Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.16966 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Veterinary Internal Medicine, 2024. Verfasst von Sara A Jablonski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. Hauptthemen laut MEDLINE: Protein-Losing Enteropathies, Dog Diseases, Lymphangiectasis, Intestinal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
More than 50% of dogs with protein-losing enteropathy (PLE) fail to respond to standard therapies. Octreotide, a somatostatin analogue, is used in cases of intestinal lymphangiectasia (IL) in humans with some success.
Objectives
Describe the use of octreotide in dogs with PLE including reason for and details of prescription, adverse effects, and apparent response. Animals Eighteen dogs with PLE, 13 with histopathology available. Ninety-two percent (12/13) had IL diagnosed on biopsy. All 13 dogs had intestinal inflammatory infiltrates noted.
Methods
Multicenter, retrospective, descriptive study. Cases were volunteered for inclusion by individual attending veterinarians who reported the use of octreotide in cases of PLE.
Results
In 16/18 (89%) cases octreotide was prescribed to PLE dogs with a clinical suspicion or confirmed diagnosis of IL that were refractory to standard therapies. Median serum albumin at the time of octreotide prescription was 1.7 g/dL (range, 1.0-3.1 g/dL). The median dose of octreotide prescribed was 20 μg/kg, SQ, daily with a range of 4-39 μg/kg, SQ, daily. Adverse effects were noted in 3/18 (17%, 95% CI [4%, 41%]) of dogs; discontinuation of the drug was necessary in 1 dog. Improvement in clinical signs was noted in 6/12 (50%, 95% CI [21%, 79%]). Conclusions and Clinical Importance Octreotide was most commonly prescribed to dogs with PLE and suspected or confirmed IL that had failed to respond to standard therapies. Though a benefit to PLE dogs cannot be confirmed, octreotide was well tolerated by the majority of dogs at the doses prescribed in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
- MI, BluePearl Veterinary Partners, Eden Prairie, Minnesota, USA.
- Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
ORCID-Profile: Sara A Jablonski, M Katherine Tolbert
Zitieren
APA
Jablonski, S. A., Mazepa, A. S. W., & Tolbert, M. K. (2024). Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16966
Vancouver
Jablonski SA, Mazepa ASW, Tolbert MK. Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.16966
BibTeX
@article{Jablonski2024,
author = {Jablonski, Sara A and Mazepa, Allison S W and Tolbert, M Katherine},
title = {Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.16966}
}
EUVIMED